Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group

Calvin C. Wu, Michael Econs, Linda DiMeglio, Karl L. Insogna, Michael A. Levine, Paul J. Orchard, Weston P. Miller, Anna Petryk, Eric T. Rush, Dolores M. Shoback, Leanne M. Ward, Lynda E. Polgreen

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Background: Osteopetrosis encompasses a group of rare metabolic bone diseases characterized by impaired osteoclast activity or development, resulting in high bone mineral density. Existing guidelines focus on treatment of the severe infantile forms with hematopoietic cell transplantation (HCT) but do not address the management of patients with less severe forms for whom HCT is not the standard of care. Therefore, our objective was to develop expert consensus guidelines for the management of these patients.

Methods: A modified Delphi method was used to build consensus among participants of the Osteopetrosis Working Group, with responses to an anonymous online survey used to identify areas of agreement and conflict and develop a follow-up survey. The strength of recommendations and quality of evidence was graded using the Grading of Recommendations Assessment, Development and Evaluation system.

Results: Consensus was found in the areas of diagnosis, monitoring, and treatment. We recommend relying on characteristic radiographic findings to make the diagnosis and found that genetic testing adds important information by identifying mutations associated with unique disease complications. We recommend ongoing monitoring for changes in mineral metabolism and other complications, including cranial nerve impingement, anemia, leukopenia, and dental disease. We suggest that calcitriol should not be used in high doses and instead recommend symptom-based supportive therapy for disease complications because noninfantile osteopetrosis has no effective treatment.

Conclusions: Scarcity of published studies on osteopetrosis reduce the ability to develop evidence-based guidelines for the management of these patients. Expert opinion-based guidelines for this rare condition are nevertheless important to enable improved care.

Original languageEnglish (US)
Pages (from-to)3111-3123
Number of pages13
JournalThe Journal of clinical endocrinology and metabolism
Volume102
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Osteopetrosis
Guidelines
Cell Transplantation
Minerals
Bone
Stomatognathic Diseases
Cranial Nerves
Monitoring
Calcitriol
Metabolic Bone Diseases
Leukopenia
Expert Testimony
Genetic Testing
Osteoclasts
Therapeutics
Standard of Care
Metabolism
Bone Density
Anemia
Mutation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Diagnosis and Management of Osteopetrosis : Consensus Guidelines From the Osteopetrosis Working Group. / Wu, Calvin C.; Econs, Michael; DiMeglio, Linda; Insogna, Karl L.; Levine, Michael A.; Orchard, Paul J.; Miller, Weston P.; Petryk, Anna; Rush, Eric T.; Shoback, Dolores M.; Ward, Leanne M.; Polgreen, Lynda E.

In: The Journal of clinical endocrinology and metabolism, Vol. 102, No. 9, 01.09.2017, p. 3111-3123.

Research output: Contribution to journalReview article

Wu, CC, Econs, M, DiMeglio, L, Insogna, KL, Levine, MA, Orchard, PJ, Miller, WP, Petryk, A, Rush, ET, Shoback, DM, Ward, LM & Polgreen, LE 2017, 'Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group', The Journal of clinical endocrinology and metabolism, vol. 102, no. 9, pp. 3111-3123. https://doi.org/10.1210/jc.2017-01127
Wu, Calvin C. ; Econs, Michael ; DiMeglio, Linda ; Insogna, Karl L. ; Levine, Michael A. ; Orchard, Paul J. ; Miller, Weston P. ; Petryk, Anna ; Rush, Eric T. ; Shoback, Dolores M. ; Ward, Leanne M. ; Polgreen, Lynda E. / Diagnosis and Management of Osteopetrosis : Consensus Guidelines From the Osteopetrosis Working Group. In: The Journal of clinical endocrinology and metabolism. 2017 ; Vol. 102, No. 9. pp. 3111-3123.
@article{124f63c9040d4644969ce1ac1833833b,
title = "Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group",
abstract = "Background: Osteopetrosis encompasses a group of rare metabolic bone diseases characterized by impaired osteoclast activity or development, resulting in high bone mineral density. Existing guidelines focus on treatment of the severe infantile forms with hematopoietic cell transplantation (HCT) but do not address the management of patients with less severe forms for whom HCT is not the standard of care. Therefore, our objective was to develop expert consensus guidelines for the management of these patients.Methods: A modified Delphi method was used to build consensus among participants of the Osteopetrosis Working Group, with responses to an anonymous online survey used to identify areas of agreement and conflict and develop a follow-up survey. The strength of recommendations and quality of evidence was graded using the Grading of Recommendations Assessment, Development and Evaluation system.Results: Consensus was found in the areas of diagnosis, monitoring, and treatment. We recommend relying on characteristic radiographic findings to make the diagnosis and found that genetic testing adds important information by identifying mutations associated with unique disease complications. We recommend ongoing monitoring for changes in mineral metabolism and other complications, including cranial nerve impingement, anemia, leukopenia, and dental disease. We suggest that calcitriol should not be used in high doses and instead recommend symptom-based supportive therapy for disease complications because noninfantile osteopetrosis has no effective treatment.Conclusions: Scarcity of published studies on osteopetrosis reduce the ability to develop evidence-based guidelines for the management of these patients. Expert opinion-based guidelines for this rare condition are nevertheless important to enable improved care.",
author = "Wu, {Calvin C.} and Michael Econs and Linda DiMeglio and Insogna, {Karl L.} and Levine, {Michael A.} and Orchard, {Paul J.} and Miller, {Weston P.} and Anna Petryk and Rush, {Eric T.} and Shoback, {Dolores M.} and Ward, {Leanne M.} and Polgreen, {Lynda E.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1210/jc.2017-01127",
language = "English (US)",
volume = "102",
pages = "3111--3123",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Diagnosis and Management of Osteopetrosis

T2 - Consensus Guidelines From the Osteopetrosis Working Group

AU - Wu, Calvin C.

AU - Econs, Michael

AU - DiMeglio, Linda

AU - Insogna, Karl L.

AU - Levine, Michael A.

AU - Orchard, Paul J.

AU - Miller, Weston P.

AU - Petryk, Anna

AU - Rush, Eric T.

AU - Shoback, Dolores M.

AU - Ward, Leanne M.

AU - Polgreen, Lynda E.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background: Osteopetrosis encompasses a group of rare metabolic bone diseases characterized by impaired osteoclast activity or development, resulting in high bone mineral density. Existing guidelines focus on treatment of the severe infantile forms with hematopoietic cell transplantation (HCT) but do not address the management of patients with less severe forms for whom HCT is not the standard of care. Therefore, our objective was to develop expert consensus guidelines for the management of these patients.Methods: A modified Delphi method was used to build consensus among participants of the Osteopetrosis Working Group, with responses to an anonymous online survey used to identify areas of agreement and conflict and develop a follow-up survey. The strength of recommendations and quality of evidence was graded using the Grading of Recommendations Assessment, Development and Evaluation system.Results: Consensus was found in the areas of diagnosis, monitoring, and treatment. We recommend relying on characteristic radiographic findings to make the diagnosis and found that genetic testing adds important information by identifying mutations associated with unique disease complications. We recommend ongoing monitoring for changes in mineral metabolism and other complications, including cranial nerve impingement, anemia, leukopenia, and dental disease. We suggest that calcitriol should not be used in high doses and instead recommend symptom-based supportive therapy for disease complications because noninfantile osteopetrosis has no effective treatment.Conclusions: Scarcity of published studies on osteopetrosis reduce the ability to develop evidence-based guidelines for the management of these patients. Expert opinion-based guidelines for this rare condition are nevertheless important to enable improved care.

AB - Background: Osteopetrosis encompasses a group of rare metabolic bone diseases characterized by impaired osteoclast activity or development, resulting in high bone mineral density. Existing guidelines focus on treatment of the severe infantile forms with hematopoietic cell transplantation (HCT) but do not address the management of patients with less severe forms for whom HCT is not the standard of care. Therefore, our objective was to develop expert consensus guidelines for the management of these patients.Methods: A modified Delphi method was used to build consensus among participants of the Osteopetrosis Working Group, with responses to an anonymous online survey used to identify areas of agreement and conflict and develop a follow-up survey. The strength of recommendations and quality of evidence was graded using the Grading of Recommendations Assessment, Development and Evaluation system.Results: Consensus was found in the areas of diagnosis, monitoring, and treatment. We recommend relying on characteristic radiographic findings to make the diagnosis and found that genetic testing adds important information by identifying mutations associated with unique disease complications. We recommend ongoing monitoring for changes in mineral metabolism and other complications, including cranial nerve impingement, anemia, leukopenia, and dental disease. We suggest that calcitriol should not be used in high doses and instead recommend symptom-based supportive therapy for disease complications because noninfantile osteopetrosis has no effective treatment.Conclusions: Scarcity of published studies on osteopetrosis reduce the ability to develop evidence-based guidelines for the management of these patients. Expert opinion-based guidelines for this rare condition are nevertheless important to enable improved care.

UR - http://www.scopus.com/inward/record.url?scp=85030757799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030757799&partnerID=8YFLogxK

U2 - 10.1210/jc.2017-01127

DO - 10.1210/jc.2017-01127

M3 - Review article

C2 - 28655174

AN - SCOPUS:85030757799

VL - 102

SP - 3111

EP - 3123

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 9

ER -